CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Activities:
Net (loss) income	$ (4,170)	$ 985
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation expense	94	94
Amortization expense	596	546
Stock-based compensation expense	187	165
Deferred income taxes	(723)	(303)
Net loss from equity securities	14	256
Acquired in-process research and development expenses	4,131	481
In-process research and development impairment	2,430	0
Other	119	63
Changes in operating assets and liabilities:
Accounts receivable, net	(66)	635
Inventories	(45)	(227)
Prepaid expenses and other	(37)	26
Accounts payable	72	(272)
Income tax assets and liabilities, net	(208)	(161)
Accrued and other liabilities	(175)	(543)
Net cash provided by operating activities	2,219	1,744
Investing Activities:
Purchases of marketable debt securities	(244)	(527)
Proceeds from sales of marketable debt securities	2,265	167
Proceeds from maturities of marketable debt securities	327	324
Acquisitions, including in-process research and development, net of cash acquired	(4,043)	(551)
Purchases of equity securities	(410)	(125)
Capital expenditures	(105)	(109)
Other	5	(5)
Net cash used in investing activities	(2,207)	(826)
Financing Activities:
Proceeds from issuances of common stock	146	97
Repurchases of common stock under repurchase programs	(400)	(400)
Payments of dividends	(990)	(969)
Other	(116)	(135)
Net cash used in financing activities	(1,361)	(1,406)
Effect of exchange rate changes on cash and cash equivalents	(18)	13
Net change in cash and cash equivalents	(1,367)	(476)
Cash and cash equivalents at beginning of period	6,085	5,412
Cash and cash equivalents at end of period	$ 4,718	$ 4,936